Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

Update for the Week Ending April 25, 2020

4/28/2020

 
Regulatory Update
 
The FDA approved sacituzumab govitecan (Trodelvy, Immunomedics) on 4/22/2020 to treat resistant metastatic triple-negative breast cancer. Trodelvy has a boxed warning about the potential risks for severe diarrhea and neutropenia.
 
Biogen has delayed plans to file a BLA for aducanumab (for the treatment of Alzheimer’s disease) from early 2020 to 3Q20.
 
Announced Research Updates
 
Scynexis announced that in the 188 patient, Phase III, VANISH-306 trial, treatment with ibrexafungerp resulted in clinical cure at day 10 in 68.3% of patients compared to an unknown percentage that received placebo in female patients with vulvovaginal candidiasis. Scynexis plans to submit an NDA for ibrexafungerp in second half of 2020.
 
Cara announced that in the 12-week, 473 patient, Phase III, KALM-2 trial, 54% of patients treated with difelikefalin had a 3-point or > improvement in the weekly mean WI-NRS compared to 42% with placebo in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus. Cara plans to submit an NDA for difelikefalin by the end of 2020.
 
Myovant announced that in the 24-week, 600 patient, Phase III, SPIRIT 2 trial, treatment with relugolix plus estradiol and norethindrone reduced dysmenorrhea (75.2% vs 30.4%) and non-menstrual pelvic pain (66.0% vs 42.6%) compared to placebo in patients with with pain associated with endometriosis. Myovant submitted an NDA for relugolix for the treatment of prostate cancer in April 2020 and plans to submit an NDA for use of the drug in the treatment of uterine fibroids in May 2020.
 
GSK announced that interim data from 70 patients enrolled in the Phase III GARNET trial, suggested a 43% objective response rate with treatment with dostarlimab in patients with previously treated recurrent or advanced mismatch repair (MMR)-deficient endometrial cancer.
 
Published Research Updates
 
In a 12-week, 708 patient, Phase III trial, 18.4% of patients treated with clascoterone 1% cream achieved an Investigator's Global Assessment score of 0 (clear) or 1 (almost clear), and a 2-grade or greater improvement, compared to 9% with placebo in patients with moderate or severe facial acne. In a 12-week, 732 patient, Phase III trial, 20.3% of patients treated with clascoterone 1% cream achieved an Investigator's Global Assessment score of 0 (clear) or 1 (almost clear), and a 2-grade or greater improvement, compared to 6.5% with placebo in patients with moderate or severe facial acne.
 
In the 18-month, 95 patient, Phase III, SAkuraStar trial, 70% of patients treated with satralizumab were relapse-free compared to 50% with placebo in patients with neuromyelitis optica spectrum disorder.
 
In a 28-day, 29 patient, Phase I, open-label trial, 78.6% of patients treated with itacitinib 200 mg plus corticosteroids and 66.7% of patients receiving 300 mg  plus corticosteroids achieved an overall response in patients who developed acute graft-versus-host disease following allogeneic hematopoietic cell transplantation.


Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.